T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union’s Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T-cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment i
All European adult patients who received CAR T-cell therapy for a hematologic malignancy can participate by filling in a digital survey.
Engineered T-cell therapy is a revolutionary cancer treatment where a patient’s immune cells are reprogrammed to seek and destroy cancer cells. This transformative treatment has the potential to cure cancer with a single shot. This therapy is approved and available in the EU for the treatment of leukemia and has the potential to become a blockbuster therapy for other types of cancer, as well as infectious diseases and autoimmune diseases in the future.
ictpatras.gr | Ινστιτούτο Κυτταρικών Θεραπειών | Πανεπιστημιακό Ερευνητικό Κέντρο, Πανεπιστημίου Πατρών
RIBOLUTION Biomarker Center - Fraunhofer IZI
T2Evolve | The homepage of T2EVOLVE, a consortium working to accelerate the process of developing CAR T-cell therapy in the Euro
RIBOLUTION Biomarker Center - Fraunhofer IZI